June 2016

23 Jun

133

Apellis Announces Positive Results from Phase 1 Clinical Trials of APL-2, a C3 Complement Inhibitor

In All, Portfolio

LOUISVILLE, Ky., June 23, 2016 – Apellis Pharmaceuticals, Inc. today announced positive results from two Phase 1 clinical trials of its complement C3 inhibitor, APL-2. The trials were randomized, double-blind, placebo-controlled, single and multiple ascending dose studies designed to assess the safety, tolerability, pharmacokinetics (PK)…

20 Jun

113

Mironid Announces Closing of £4.3 million Series A Financing

In All, Portfolio

Glasgow, Scotland, UK, 20th June 2016: Mironid Ltd, a leader in cell signalling directed drug development, today announced the closing of its Series A funding round of £4.3 million ($6.2 million), which will support the Company’s internal research and preclinical development programmes, focused on degenerative…